CL2015000354A1 - Compuestos derivados de piridina; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento o profilaxis de la diabetes, aterosclerosis, entre otras. - Google Patents
Compuestos derivados de piridina; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento o profilaxis de la diabetes, aterosclerosis, entre otras.Info
- Publication number
- CL2015000354A1 CL2015000354A1 CL2015000354A CL2015000354A CL2015000354A1 CL 2015000354 A1 CL2015000354 A1 CL 2015000354A1 CL 2015000354 A CL2015000354 A CL 2015000354A CL 2015000354 A CL2015000354 A CL 2015000354A CL 2015000354 A1 CL2015000354 A1 CL 2015000354A1
- Authority
- CL
- Chile
- Prior art keywords
- prophylaxis
- atherosclerosis
- diabetes
- pyridine
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12181247 | 2012-08-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2015000354A1 true CL2015000354A1 (es) | 2015-10-23 |
Family
ID=46851300
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2015000354A CL2015000354A1 (es) | 2012-08-21 | 2015-02-16 | Compuestos derivados de piridina; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento o profilaxis de la diabetes, aterosclerosis, entre otras. |
Country Status (24)
Country | Link |
---|---|
US (1) | US9409882B2 (es) |
EP (1) | EP2888244A1 (es) |
JP (1) | JP2015530997A (es) |
KR (1) | KR20150044947A (es) |
CN (1) | CN104583198A (es) |
AR (1) | AR092172A1 (es) |
AU (1) | AU2013305102A1 (es) |
BR (1) | BR112015003217A2 (es) |
CA (1) | CA2879796A1 (es) |
CL (1) | CL2015000354A1 (es) |
CO (1) | CO7200259A2 (es) |
CR (1) | CR20150073A (es) |
EA (1) | EA025166B1 (es) |
HK (1) | HK1206716A1 (es) |
IL (1) | IL237128A0 (es) |
IN (1) | IN2015DN00962A (es) |
MA (1) | MA37893A1 (es) |
MX (1) | MX2015002026A (es) |
PE (1) | PE20150995A1 (es) |
PH (1) | PH12015500262A1 (es) |
SG (1) | SG11201500900YA (es) |
TW (1) | TW201412728A (es) |
WO (1) | WO2014029722A1 (es) |
ZA (1) | ZA201500625B (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2775781T3 (es) * | 2016-02-26 | 2020-07-28 | Hoffmann La Roche | Derivados de pirrolidina novedosos |
JOP20190181B1 (ar) | 2017-01-24 | 2023-09-17 | Astellas Pharma Inc | مركب برولين أميد به استبدال بواسطة فينيل داي فلوروميثيل |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9903610D0 (sv) | 1999-10-06 | 1999-10-06 | Astra Ab | Novel compounds II |
JP2008526840A (ja) | 2005-01-06 | 2008-07-24 | アストラゼネカ アクチボラグ | 新規化合物 |
EP1979345B1 (en) | 2006-01-24 | 2009-11-04 | Actelion Pharmaceuticals Ltd. | Novel pyridine derivatives |
NZ581259A (en) * | 2007-05-09 | 2012-07-27 | Vertex Pharma | Modulators of cystic fibrosis transmembrane conductance regulator |
CN102026978A (zh) | 2007-11-30 | 2011-04-20 | 霍夫曼-拉罗奇有限公司 | 吡啶化合物 |
US20110028448A1 (en) | 2008-03-06 | 2011-02-03 | Martin Bolli | Pyridine compounds |
PL2421826T3 (pl) | 2009-04-20 | 2014-03-31 | Hoffmann La Roche | Pochodne proliny jako inhibitory katepsyn |
US8394834B2 (en) * | 2009-08-25 | 2013-03-12 | Hoffman-La Roche Inc. | Pyrrolidines as NK3 receptor antagonists |
WO2013049559A1 (en) | 2011-09-30 | 2013-04-04 | Endo Pharmaceuticals Inc. | Pyridine derivatives |
-
2013
- 2013-08-19 JP JP2015527877A patent/JP2015530997A/ja active Pending
- 2013-08-19 EA EA201590363A patent/EA025166B1/ru not_active IP Right Cessation
- 2013-08-19 AU AU2013305102A patent/AU2013305102A1/en not_active Abandoned
- 2013-08-19 CA CA2879796A patent/CA2879796A1/en not_active Abandoned
- 2013-08-19 PE PE2015000231A patent/PE20150995A1/es not_active Application Discontinuation
- 2013-08-19 CN CN201380043572.1A patent/CN104583198A/zh active Pending
- 2013-08-19 MA MA37893A patent/MA37893A1/fr unknown
- 2013-08-19 BR BR112015003217A patent/BR112015003217A2/pt not_active Application Discontinuation
- 2013-08-19 IN IN962DEN2015 patent/IN2015DN00962A/en unknown
- 2013-08-19 WO PCT/EP2013/067218 patent/WO2014029722A1/en active Application Filing
- 2013-08-19 SG SG11201500900YA patent/SG11201500900YA/en unknown
- 2013-08-19 MX MX2015002026A patent/MX2015002026A/es unknown
- 2013-08-19 TW TW102129708A patent/TW201412728A/zh unknown
- 2013-08-19 EP EP13750339.7A patent/EP2888244A1/en not_active Withdrawn
- 2013-08-19 KR KR20157006927A patent/KR20150044947A/ko not_active Application Discontinuation
- 2013-08-20 AR ARP130102939A patent/AR092172A1/es unknown
-
2015
- 2015-01-27 ZA ZA2015/00625A patent/ZA201500625B/en unknown
- 2015-02-05 IL IL237128A patent/IL237128A0/en unknown
- 2015-02-06 PH PH12015500262A patent/PH12015500262A1/en unknown
- 2015-02-09 CO CO15025964A patent/CO7200259A2/es unknown
- 2015-02-11 CR CR20150073A patent/CR20150073A/es not_active Application Discontinuation
- 2015-02-16 CL CL2015000354A patent/CL2015000354A1/es unknown
- 2015-02-20 US US14/627,175 patent/US9409882B2/en not_active Expired - Fee Related
- 2015-07-27 HK HK15107145.2A patent/HK1206716A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
AR092172A1 (es) | 2015-03-25 |
EP2888244A1 (en) | 2015-07-01 |
PE20150995A1 (es) | 2015-06-29 |
CO7200259A2 (es) | 2015-02-27 |
JP2015530997A (ja) | 2015-10-29 |
WO2014029722A1 (en) | 2014-02-27 |
AU2013305102A1 (en) | 2015-02-12 |
CR20150073A (es) | 2015-03-13 |
MA37893A1 (fr) | 2017-08-31 |
HK1206716A1 (en) | 2016-01-15 |
TW201412728A (zh) | 2014-04-01 |
US9409882B2 (en) | 2016-08-09 |
EA025166B1 (ru) | 2016-11-30 |
MX2015002026A (es) | 2015-06-05 |
CA2879796A1 (en) | 2014-02-27 |
ZA201500625B (en) | 2016-08-31 |
EA201590363A1 (ru) | 2015-06-30 |
CN104583198A (zh) | 2015-04-29 |
SG11201500900YA (en) | 2015-03-30 |
IL237128A0 (en) | 2015-03-31 |
BR112015003217A2 (pt) | 2017-07-04 |
KR20150044947A (ko) | 2015-04-27 |
US20150307472A1 (en) | 2015-10-29 |
PH12015500262A1 (en) | 2015-03-30 |
IN2015DN00962A (es) | 2015-06-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2013003372A1 (es) | Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes. | |
CL2014002757A1 (es) | Compuestos derivados de benzamida para inhibir la actividad de abl1, abl2 y bcr-abl1, composicion farmaceutica; y uso en el tratamiento del cancer. | |
CL2014001858A1 (es) | Compuestos derivados de pirrolidina-2-carboxamidas sustituidas, antagonistas de mdm2; composicion farmacetica; y su uso en el tratamiento o profilaxis del cancer. | |
CL2014002873A1 (es) | Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer. | |
CL2014001060A1 (es) | Compuestos derivados de aril-quinolina; proceso de obtencion; composicion farmaceutica que los comprende y uso en el tratamiento o profilaxis de la diabetes tipo 2, la aterosclerosis, cancer, entre otras enfermedades. | |
BR112014023937A2 (pt) | composição farmacêutica, agente farmacêutico de combinação e método de tratamento | |
CL2014002093A1 (es) | Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas. | |
CL2014002983A1 (es) | Compuestos derivados de 1h-pirazolo[3,4-b]piridina, como inhibidores de una o mas proteinas en la ruta de wnt; composicion farmaceutica que los comprende, util para el tratamiento de cancer, retinopatia diabetica, fibrosis pulmonar, artritis reumatoide, enfermedad de alzheimer, entre otras. | |
PH12015500983A1 (en) | Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections | |
CL2013001891A1 (es) | Compuestos heterociclicos fusionados; composicion farmaceutica y uso en el tratamiento de la degeneracion macular asociada con la edad. | |
BR112015003397A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente. | |
CO6791606A2 (es) | Composiciones y métodos para el tratamiento en aplicaciones clínicas de amplio espectro, no diferenciadas o combinadas | |
CL2014002919A1 (es) | Compuestos derivados de 1h-indol-4-il-metil-(heterociclo benzofusionado); composicion y combinacion farmaceutica; y uso en el tratamiento de un trastorno mediado por la activacion del complemento o la ruta alternativa del mismo. | |
CL2014002557A1 (es) | Compuestos bicíclicos de pirazinona; procedimiento de preparacion; composicion farmaceutica; kit; y uso en el tratamiento y/o prevencion de enfermedades cardiovasculares, cancer, entre otras. | |
BR112015003259A2 (pt) | composto, composição farmacêutica, e, composição de vacina. | |
CL2014000849A1 (es) | Compuestos derivados de benzilindazoles sustituido, inhibidores de la quinasa bub1; procedimiento de fabricacion; composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento de enfermedades hiperproliferativas. | |
CL2015001014A1 (es) | Composicion de silicato de zirconio microporoso, util para el tratamiento de la hipercalemia | |
CL2015001318A1 (es) | Compuestos derivados de pirazina, agonistas del receptor cb2; proceso de obtencion; composicion farmaceutica y el uso en el tratamiento de enfermedades tales como aterosclerosis, glaucoma, diabetes, entre otras. | |
CL2008000875A1 (es) | Compuestos derivados de imidazolidin-2-ona; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento y/o profilaxis de enfermedades tales como dislipidemia, diabetes, enfermedades inflamatorias, entre otras. | |
CL2014001861A1 (es) | Compuestos derivados de bencil sulfonamida, inhibidores de mogat-2; compuesto cristalino; composicion farmaceutica; y su uso en el tratamiento de la hipertrigliceridemia. | |
HK1222563A1 (zh) | 藥物組合物、製備及其用途 | |
CL2015001202A1 (es) | Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer. | |
EP3034082A4 (en) | Pharmaceutical composition for treating or preventing neuropsychitric disease, containing flavone-6-c-glucose derivatives as active ingredients | |
CL2014003429A1 (es) | Compuestos especificos derivados de indanosulfamida; composicion farmaceutica que los comprende, utiles en el tratamiento e la epilepsia. | |
CL2014002048A1 (es) | Compuestos derivados de 4-(benzoimidazol-2-il)-tiazol y derivados aza relacionados; composicion farmaceutica; y uso en la prevencion y el tratamiento de trastornos autoinmunes, inflamatorios, enfermedades infecciosas, entre otras. |